Thebainetest Statistics on Market Size, Growth, Production, Sales Volume, Sales Price, Market Share and Import vs Export 

Thebaine Market Summary Highlights

The Thebaine Market is emerging as a strategically important segment within the pharmaceutical alkaloids industry due to its critical role as a precursor in the production of semi-synthetic opioids such as oxycodone, buprenorphine, naloxone, and naltrexone. Thebaine, a naturally occurring opiate alkaloid derived primarily from Papaver somniferum (opium poppy), has no direct analgesic use but serves as an essential intermediate in controlled pharmaceutical manufacturing. As global healthcare systems continue to prioritize regulated pain management, opioid dependence treatment, and emergency overdose reversal drugs, the Thebaine Market is witnessing steady structural demand growth.

The Thebaine Market Size is expanding in parallel with the increasing demand for controlled active pharmaceutical ingredients (APIs). Expansion of pharmaceutical manufacturing capacity in countries such as India, Australia, France, Spain, and Turkey is strengthening supply chain resilience. For instance, licensed poppy cultivation areas dedicated to pharmaceutical alkaloids increased by an estimated 6.8% in 2025 compared to 2024, directly supporting raw material availability.

Another important factor shaping the Thebaine Market is the shift toward abuse-deterrent opioid formulations and opioid antagonists. Governments and regulatory bodies are encouraging the development of safer pain management drugs, thereby increasing the requirement for thebaine-derived molecules. For example, naloxone distribution programs expanded by approximately 11% globally in 2025, creating additional downstream demand.

Technological improvements in alkaloid extraction and semi-synthetic conversion efficiency are also improving yield ratios. Modern extraction facilities are achieving 8–12% higher alkaloid recovery rates compared to conventional processing technologies, improving cost structures and supply consistency.

From a regional standpoint, Asia-Pacific is strengthening its position due to API manufacturing growth, while Europe maintains strong regulatory pharmaceutical demand. North America remains driven by high consumption of opioid dependence treatment drugs rather than traditional painkillers, reflecting prescribing pattern changes.

Key statistical highlights of the Thebaine Market include:

• The Thebaine Market Size is projected to grow at an estimated CAGR of 5.9% between 2025 and 2032 driven by pharmaceutical intermediate demand.
• Pharmaceutical applications account for approximately 92% of total Thebaine Market demand in 2025, reflecting its limited non-medical usage.
• Semi-synthetic opioid production derived from thebaine is forecast to increase by 7.2% in 2026 due to rising demand for controlled pain therapeutics.
• Licensed cultivation of high-thebaine poppy varieties is expected to expand by 5–7% annually through 2030.
• Asia-Pacific accounts for nearly 34% of Thebaine Market processing capacity in 2025, driven by API production clusters.
• Opioid dependence treatment drugs such as buprenorphine and naltrexone are contributing to nearly 18% of thebaine consumption growth.
• Pharmaceutical R&D investments related to opioid antagonists increased by approximately 9.4% between 2024 and 2026.
• Advanced alkaloid extraction technologies improved production efficiency by 10% on average in 2025.
• Government regulatory monitoring covers nearly 100% of global thebaine production, making it one of the most tightly regulated pharmaceutical intermediates.
• Contract manufacturing of controlled APIs is expected to increase by 6.5% in 2026, supporting Thebaine Market expansion.

Rising Demand for Semi-Synthetic Opioid Pharmaceuticals Driving Thebaine Market Expansion

One of the most important structural drivers of the Thebaine Market is the rising demand for semi-synthetic opioids used in controlled clinical settings. Thebaine functions as a chemical backbone for drugs such as oxycodone and buprenorphine, which continue to see controlled medical use despite tighter prescription regulations.

For instance, global production of semi-synthetic opioid APIs increased by approximately 6.3% in 2025 due to continued surgical procedure volumes and chronic disease management requirements. Growth in orthopedic procedures, cancer pain treatment, and post-operative care remains a contributing factor.

Examples of growth drivers include:

• Global surgical procedures increasing by nearly 4.5% annually
• Cancer incidence increasing approximately 3.2% yearly, increasing oncology pain management demand
• Chronic pain prevalence affecting nearly 22% of adults globally in 2025

As a result, pharmaceutical companies continue to maintain minimum production thresholds of thebaine derivatives to ensure medical supply stability. The Thebaine Market therefore benefits from baseline demand stability rather than cyclical consumption patterns.

Another important factor is the increasing adoption of partial opioid agonists such as buprenorphine for addiction treatment. Buprenorphine prescriptions increased by approximately 8% in regulated treatment programs between 2024 and 2026, indirectly strengthening demand fundamentals within the Thebaine Market.

Expansion of Opioid Dependence Treatment Programs Supporting Thebaine Market Growth

A major structural transition within the Thebaine Market involves the shift from traditional opioid painkillers toward opioid dependence treatment drugs. This transformation is reshaping the demand structure from purely analgesic applications toward rehabilitation pharmaceuticals.

For example, the number of medically supervised opioid substitution therapy programs increased by nearly 10% globally between 2023 and 2025. This is creating sustained demand for thebaine-derived molecules such as:

• Buprenorphine
• Naloxone
• Naltrexone

Naloxone demand is particularly increasing due to emergency overdose response programs. Distribution volumes increased approximately 11–13% in 2025 as public health systems expanded emergency preparedness strategies.

Several structural drivers supporting this trend include:

• Increasing healthcare funding toward addiction treatment
• Mandatory availability of overdose reversal drugs in emergency services
• Expansion of harm-reduction healthcare programs

For instance, emergency medical systems in developed healthcare markets increased naloxone stocking requirements by approximately 15% between 2024 and 2026.

This transition is important because it provides a more stable long-term demand outlook for the Thebaine Market compared to traditional opioid prescribing, which is declining in some regions due to regulatory pressure.

Licensed Opium Poppy Cultivation and Supply Chain Regulation Strengthening Thebaine Market Stability

Supply security remains a defining factor influencing the Thebaine Market. Because thebaine originates from regulated opium poppy cultivation, production is limited to licensed geographies operating under international narcotics control frameworks.

Major producing regions include:

• Australia (high-thebaine poppy varieties)
• France
• Spain
• Turkey
• India

Australia remains a leading producer of high-thebaine poppy strains, accounting for nearly 40% of pharmaceutical-grade thebaine raw material supply in 2025 due to specialized crop genetics.

Supply chain improvements include:

• Precision agriculture improving alkaloid yield per hectare by 5–8%
• Mechanized harvesting improving raw material consistency
• Genetic breeding programs increasing thebaine concentration ratios

For instance, new poppy cultivars introduced between 2023 and 2025 demonstrated approximately 9% higher thebaine content compared to conventional varieties.

These improvements directly impact Thebaine Market economics by:

• Reducing raw material variability
• Improving extraction efficiency
• Lowering production losses

Additionally, strict regulatory monitoring is improving supply chain transparency. Digital tracking of controlled alkaloids increased by nearly 14% across pharmaceutical supply networks in 2025, strengthening compliance and traceability.

Growth of Controlled API Manufacturing in Asia Supporting Thebaine Market Development

The expansion of pharmaceutical API manufacturing hubs is another major factor influencing the Thebaine Market. Countries such as India and China are expanding their controlled substance API manufacturing capabilities due to cost competitiveness and technical expertise.

For example:

• Controlled API manufacturing capacity increased approximately 7% in Asia in 2025
• Pharmaceutical contract manufacturing demand grew by 6–8%
• Export of regulated APIs increased by approximately 5.5%

India remains a key processing center due to its strong generic pharmaceutical manufacturing ecosystem. API parks and pharmaceutical clusters are enabling integrated production of controlled intermediates including thebaine derivatives.

Growth drivers include:

• Lower production costs (20–30% lower compared to Western markets)
• Skilled pharmaceutical chemistry workforce
• Regulatory alignment with global pharmaceutical standards

For instance, expansion of pharmaceutical manufacturing zones is expected to increase controlled API output capacity by nearly 12% by 2028, indirectly supporting Thebaine Market processing demand.

This trend is particularly important because thebaine is rarely consumed directly and instead moves through value-added pharmaceutical conversion chains. Therefore, API manufacturing growth directly translates into Thebaine Market expansion.

Technological Advancements in Alkaloid Extraction Improving Thebaine Market Efficiency

Technological modernization in alkaloid extraction and purification is significantly improving productivity across the Thebaine Market. Traditional solvent extraction methods are increasingly being replaced by advanced chromatography and continuous processing systems.

Technology improvements include:

• Continuous extraction systems improving yield by 10–12%
• Process automation reducing contamination risks by 6%
• AI-driven quality monitoring improving batch consistency

For example, modern pharmaceutical alkaloid plants installed between 2022 and 2025 demonstrated operating cost reductions of nearly 8% due to improved processing efficiency.

Examples of process improvements include:

• Membrane separation improving purity levels
• Green solvent extraction reducing environmental impact
• Continuous crystallization improving scalability

Such improvements are important because pharmaceutical manufacturers require extremely high purity levels, often exceeding 99% for API intermediates. Efficiency gains therefore directly translate into better margins and improved supply reliability.

Another emerging trend is biotechnological production research. Although still in early stages, biosynthetic production pathways could potentially reduce agricultural dependence in the long term. Pilot research programs increased funding by approximately 12% between 2024 and 2026.

These technological developments are expected to gradually improve Thebaine Market supply flexibility while maintaining regulatory compliance requirements.

Geographical Demand Expansion in the Thebaine Market

The geographical demand structure of the Thebaine Market is shaped by pharmaceutical manufacturing activity, opioid dependence treatment programs, and the expansion of regulated pain management therapies. Demand remains concentrated in regions with strong pharmaceutical conversion infrastructure because thebaine is primarily consumed as an intermediate rather than a finished therapeutic compound.

North America continues to represent a significant share of the Thebaine Market demand, accounting for nearly 30% of global consumption in 2025. Demand is increasingly driven by addiction treatment drugs rather than conventional opioid prescriptions. For instance, the expansion of medication-assisted treatment programs has resulted in nearly 8% growth in buprenorphine-related pharmaceutical production between 2024 and 2026.

Europe represents another major demand center within the Thebaine Market due to strong regulatory healthcare systems and advanced pharmaceutical manufacturing. Countries with structured palliative care programs are maintaining steady demand growth. For example, chronic pain treatment programs expanded by nearly 4–5% in 2025, indirectly supporting thebaine-derived drug production.

Asia-Pacific is showing the fastest demand growth in the Thebaine Market, supported by the rapid expansion of pharmaceutical manufacturing clusters. The region is expected to grow at nearly 6–7% annually through the next decade. For instance, the growth of generic drug manufacturing has increased the consumption of pharmaceutical intermediates by approximately 7% in 2025 alone.

Emerging markets in Latin America and the Middle East are also gradually increasing their participation in the Thebaine Market due to improving healthcare infrastructure. Expansion of hospital networks and improved access to essential medicines is supporting steady intermediate demand growth of around 4–5%.

Regional Production Structure of the Thebaine Market

Production in the Thebaine Market remains highly concentrated due to international narcotics regulations that restrict cultivation and processing to licensed countries. This controlled production structure ensures stable supply but also limits rapid production expansion.

Australia remains the dominant supplier of high-thebaine poppy varieties, accounting for close to 40% of global raw material production due to its advanced agricultural biotechnology programs. The country has invested significantly in genetic optimization of poppy strains to increase alkaloid concentration levels.

India is also strengthening its role in the Thebaine Market through licensed cultivation and pharmaceutical processing expansion. Production capacity increased by approximately 5–6% in 2025 due to improvements in regulated cultivation programs and pharmaceutical processing capabilities.

Turkey continues to maintain a stable position as a traditional alkaloid processing country, benefiting from its long-standing regulatory framework and established pharmaceutical supply chains. Meanwhile, France and Spain are focusing more on processing and conversion activities rather than cultivation.

This production concentration is beneficial for the Thebaine Market because it prevents supply glut situations. Controlled production expansion typically follows pharmaceutical demand growth, allowing the market to maintain equilibrium between supply and demand.

Application Segmentation Driving the Thebaine Market

The Thebaine Market shows clear segmentation based on pharmaceutical applications, particularly semi-synthetic opioids, opioid antagonists, and addiction treatment drugs. Since thebaine has no direct therapeutic use, demand depends entirely on downstream pharmaceutical growth.

Pain management applications continue to represent the largest segment, accounting for nearly half of the Thebaine Market demand. For instance, surgical procedure volumes are increasing steadily at approximately 4% annually, supporting baseline demand for controlled analgesics derived from thebaine.

Opioid dependence treatment is emerging as the fastest growing application area. Demand for buprenorphine and naltrexone intermediates is growing by approximately 7–8% annually due to the expansion of rehabilitation programs. For example, enrollment in medically supervised addiction treatment programs increased by nearly 10% between 2024 and 2026.

Overdose reversal drugs are also contributing significantly to the Thebaine Market. Naloxone production demand is increasing at approximately 8% annually due to wider distribution policies in emergency healthcare systems.

Research applications represent a smaller but steadily growing segment. Pharmaceutical companies are increasing investment in opioid alternatives and neurological therapeutics, resulting in research demand growth of approximately 5–6%.

End-Use Industry Segmentation in the Thebaine Market

End-use demand within the Thebaine Market is dominated by pharmaceutical companies due to their role in converting thebaine into active pharmaceutical ingredients. Pharmaceutical manufacturers account for more than 70% of total demand, reflecting their central role in drug production.

Contract manufacturing organizations are increasing their share as outsourcing trends continue. Pharmaceutical companies are increasingly relying on specialized manufacturers to produce controlled intermediates, resulting in contract manufacturing demand growth of approximately 6% in 2025.

Research laboratories also represent a small but growing demand segment as pharmaceutical innovation continues. For instance, funding for non-addictive pain therapy research increased by nearly 8% between 2024 and 2026, supporting specialized intermediate demand.

Government healthcare procurement agencies also contribute to the Thebaine Market through strategic purchasing of essential medicines. Public health agencies are maintaining safety stock levels of opioid antagonists, resulting in steady procurement growth of around 5%.

Segmentation Highlights of the Thebaine Market

Key structural segmentation patterns defining the Thebaine Market include:

By application:

• Pain therapeutics remain the dominant segment with about 45–48% share
• Addiction treatment drugs represent the fastest growing segment with nearly 7–8% annual growth
• Overdose reversal drugs growing at approximately 8%
• Research applications expanding steadily around 5–6%

By region:

• North America leading consumption due to addiction treatment programs
• Europe maintaining stable demand due to regulated healthcare usage
• Asia-Pacific showing fastest industrial growth
• Emerging markets showing gradual pharmaceutical adoption

By end use:

• Pharmaceutical companies dominating demand
• Contract manufacturers increasing their share
• Research institutions supporting innovation demand
• Government agencies stabilizing procurement demand

These patterns show that the Thebaine Market growth is closely tied to healthcare system development and pharmaceutical manufacturing expansion rather than consumer-driven demand.

Thebaine Price Structure Analysis in the Thebaine Market

The Thebaine Price structure is largely influenced by regulatory controls, agricultural production costs, pharmaceutical demand, and purification requirements. Since production is tightly controlled, pricing remains relatively stable compared to other chemical intermediates.

Thebaine Price levels increased by approximately 4% in 2025 due to rising compliance costs and improvements in pharmaceutical-grade processing standards. The cost of regulatory compliance alone increased by nearly 5%, contributing to gradual pricing adjustments.

Key factors influencing Thebaine Price include licensed cultivation costs, quality testing requirements, extraction efficiency, and supply security costs. For example, improvements in pharmaceutical purity requirements have increased processing costs by nearly 4–6%, influencing Thebaine Price adjustments.

Another important influence on Thebaine Price is the limited number of producing countries. Any change in agricultural output or regulatory quotas can influence short-term pricing adjustments.

Thebaine Price Trend Analysis in the Thebaine Market

The Thebaine Price Trend reflects steady upward movement supported by healthcare demand rather than volatile commodity cycles. Price growth is generally moderate due to strict supply regulation.

Between 2024 and 2026, the Thebaine Price Trend indicates average annual increases of around 3–5%. For instance, 2026 pricing is expected to rise by approximately 4.5% due to continued pharmaceutical demand growth.

The Thebaine Price Trend is also influenced by processing efficiency improvements. Advanced extraction technologies are helping offset cost pressures by improving recovery rates, preventing excessive price increases.

Long-term Thebaine Price Trend stability is supported by factors such as controlled cultivation expansion, long-term pharmaceutical contracts, and strategic stockpiling of critical medicines. Pharmaceutical companies increased inventory buffers by approximately 6% in 2025 to avoid supply disruptions.

Overall, the Thebaine Price Trend is expected to remain moderately upward moving, supported by healthcare demand expansion and regulatory cost structures.

Thebaine Production Growth Pattern in the Thebaine Market

Thebaine production is increasing steadily as pharmaceutical companies expand intermediate supply chains. Thebaine production grew approximately 5% in 2025 due to improved cultivation practices and higher alkaloid yield crops. Thebaine production capacity is also expanding due to pharmaceutical demand growth. Thebaine production efficiency improved nearly 9% due to better extraction technologies. Thebaine production expansion is expected to remain controlled at around 4–6% annually to maintain regulatory balance. Thebaine production continues to remain closely monitored to avoid supply imbalances within the Thebaine Market.

Thebaine Price Trend and Cost Evolution in the Thebaine Market

Future cost structures within the Thebaine Market are expected to evolve gradually as process improvements balance regulatory cost pressures. Automation in pharmaceutical alkaloid processing is expected to reduce operational costs by approximately 6–8% by 2028, helping stabilize Thebaine Price increases.

The Thebaine Price Trend will continue to be influenced by agricultural costs, compliance investments, purification standards, and pharmaceutical demand growth. For instance, pharmaceutical logistics security investments increased by approximately 7% in 2025, slightly influencing overall Thebaine Price movement.

The Thebaine Price Trend is expected to maintain gradual upward movement due to continued expansion of addiction treatment programs and regulated pain management therapies. These structural healthcare drivers ensure predictable demand growth within the Thebaine Market.

Overall, the Thebaine Market continues to demonstrate characteristics of a highly regulated pharmaceutical intermediate sector where pricing stability, controlled production, and healthcare demand remain the primary influencing factors.

Key Manufacturers Operating in the Thebaine Market

The Thebaine Market is defined by a limited number of licensed manufacturers due to strict global narcotics regulations that control cultivation, extraction, and pharmaceutical conversion. This has resulted in a semi-consolidated competitive landscape where only companies with regulatory approvals and pharmaceutical processing capabilities are able to participate.

Major manufacturers operating in the Thebaine Market include Alcaliber S.A., Mallinckrodt Pharmaceuticals, Noramco, Johnson Matthey, Sanofi, Macfarlan Smith (a division of Johnson Matthey), and Tasmanian Alkaloids (Extractas Bioscience). These companies operate across different stages such as narcotic raw material processing, alkaloid extraction, and conversion into semi-synthetic opioid APIs.

These manufacturers typically operate under long-term regulatory licenses and supply agreements, which makes the Thebaine Market more stability-driven than competition-driven. The presence of regulatory barriers also prevents excessive fragmentation, resulting in predictable manufacturer positioning.

Thebaine Market Share by Manufacturers

The Thebaine Market shows moderate concentration among a few established pharmaceutical alkaloid processors. The top manufacturers collectively control nearly 60% of global processing capacity because of their access to licensed cultivation programs and advanced alkaloid extraction technologies.

Alcaliber and Macfarlan Smith together account for a significant portion of European pharmaceutical alkaloid processing, supported by their vertically integrated supply chains. Noramco maintains a strong position in North America due to its specialization in controlled pharmaceutical intermediates and opioid API development.

Tasmanian Alkaloids holds an important share in raw material production due to its specialization in high-thebaine poppy cultivation. The company’s agricultural biotechnology capabilities allow it to maintain consistent supply contracts with pharmaceutical manufacturers.

Asian pharmaceutical API producers are gradually increasing their presence in the Thebaine Market, currently representing nearly one-fifth of global processing demand. Growth in this segment is supported by expansion in generic drug manufacturing and contract API production.

Overall manufacturer share distribution is influenced by:

• Access to licensed cultivation
• Pharmaceutical conversion capacity
• Regulatory certifications
• Long-term supply agreements
• Production consistency

Companies with integrated operations typically hold stronger Thebaine Market share because they can control both upstream and downstream value chains.

Product Lines and Pharmaceutical Positioning in the Thebaine Market

Manufacturers in the Thebaine Market typically position their products as pharmaceutical intermediates rather than commodity chemicals. Thebaine is rarely marketed as a standalone product and is instead included within broader controlled substance portfolios.

Key product categories offered by manufacturers include:

• Pharmaceutical grade thebaine alkaloid
• Oripavine intermediates used in semi-synthetic opioids
• Buprenorphine intermediates
• Oxycodone precursor compounds
• Naloxone and naltrexone intermediates
• Controlled narcotic raw materials

For example, Noramco focuses on controlled substance APIs and specialty narcotic intermediates, strengthening its relevance in addiction treatment drug supply chains. Similarly, Alcaliber operates across narcotic raw materials and pharmaceutical alkaloids, allowing strong integration across the supply chain.

Johnson Matthey, through Macfarlan Smith, focuses on high-purity controlled APIs and pharmaceutical intermediates. Such specialization allows companies to maintain competitive advantage through quality compliance rather than production volume.

Manufacturers are also expanding their presence in opioid antagonist intermediates as healthcare systems increase their focus on addiction treatment and overdose prevention medicines.

Thebaine Market Share Growth Strategies Among Manufacturers

Companies in the Thebaine Market are focusing on strategic positioning rather than aggressive expansion due to regulatory limitations. Growth is typically achieved through partnerships, process efficiency, and portfolio expansion rather than price competition.

Key strategies adopted by manufacturers include:

• Vertical integration of cultivation and extraction
• Expansion of pharmaceutical API conversion capacity
• Long-term contracts with drug manufacturers
• Investment in compliance and traceability systems
• Development of high-purity alkaloid processing

Vertical integration remains one of the most effective strategies. Companies controlling cultivation through to API production can reduce supply risks and maintain stable Thebaine Market share.

Manufacturers are also investing in purification technologies to achieve pharmaceutical purity levels exceeding 99%, which improves their eligibility for regulated drug supply chains.

Another major strategy involves diversification toward addiction treatment drug intermediates. Since demand for opioid antagonists is growing faster than traditional opioid analgesics, companies are adjusting their product portfolios accordingly.

Competitive Positioning and Industry Structure of the Thebaine Market

The competitive structure of the Thebaine Market is shaped more by regulatory capability than manufacturing scale. Companies with strong compliance infrastructure tend to maintain leadership positions.

The market can be broadly divided into three manufacturer categories:

• Agricultural alkaloid producers
• Pharmaceutical intermediate manufacturers
• Finished API producers

Agricultural producers focus on high-alkaloid poppy cultivation and primary extraction. Intermediate manufacturers convert thebaine into precursor molecules, while pharmaceutical companies convert intermediates into finished APIs.

This layered structure creates interdependence between companies, reinforcing stable long-term partnerships rather than aggressive competitive displacement.

Thebaine Market competition is therefore defined by reliability of supply, purity standards, and regulatory track record rather than aggressive pricing strategies.

Production Specialization Among Thebaine Market Manufacturers

Manufacturers are increasingly specializing in particular stages of the supply chain to maintain operational efficiency. Some companies focus on high-thebaine crop development while others focus on pharmaceutical chemical conversion.

For example, Australian producers specialize in high-alkaloid crop genetics that improve extraction yields by nearly 8–10%. European processors tend to specialize in pharmaceutical conversion, while Asian manufacturers focus on cost-efficient API production.

This specialization helps the Thebaine Market maintain a balanced supply structure where each region contributes to a specific stage of the pharmaceutical value chain.

Manufacturers focusing on technological modernization are improving extraction yields, reducing waste, and improving cost efficiency. These improvements are helping companies maintain margins despite rising compliance costs.

Recent Developments Among Thebaine Market Players

Recent developments in the Thebaine Market show increasing investment in pharmaceutical supply security and controlled drug manufacturing capacity.

January 2026 – Expansion of pharmaceutical alkaloid processing capacity
Several manufacturers expanded processing facilities to support increasing demand for addiction treatment drugs. Capacity expansion projects focused on improving extraction efficiency and ensuring uninterrupted supply of controlled intermediates.

October 2025 – Investment in high-purity alkaloid processing technologies
Manufacturers upgraded purification systems to meet stricter pharmaceutical standards, particularly for opioid antagonist production.

June 2025 – Long-term pharmaceutical supply agreements
Several alkaloid processors entered multi-year supply agreements with pharmaceutical companies producing buprenorphine and naloxone based medicines.

March 2025 – Agricultural yield improvement programs
Producers introduced improved poppy seed varieties designed to increase thebaine concentration and reduce raw material variability.

2024 – Compliance modernization initiatives
Manufacturers increased investment in digital tracking systems to strengthen narcotic raw material traceability and regulatory compliance.